Other checkpoints, such as B7-H4 and FOXP3, are associated with poor prognosis, while CTLA-4 expression in certain biliary tract cancer subtypes has shown mixed outcomes, including improved disease-free intervals in hilar biliary tract cancer (63). This evidence concerns the gene CTLA4 and biliary tract cancer.